Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Free energy landscape and thermodynamics properties of novel mutations in PncA of pyrazinamide resistance isolates of Mycobacterium tuberculosis.

Journal of biomolecular structure & dynamics - 1 Jan 2024

Tahir Khan Muhammad, Dumont Elise, Chaudhry Aijaz Rasool, Wei Dong-Qing

Abstract excerpt

Pyrazinamide (PZA) is one of the first-line antituberculosis therapy, active against non-replicating Mycobacterium tuberculosis (Mtb). The conversion of PZA into pyrazinoic acid (POA), the active form, required the activity of pncA gene product pyrazinamidase (PZase) activity. Mutations occurred in pncA are the primary cause behind the PZA resistance. However, the resistance mechanism is important to explore...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Molecular Dynamics Simulation

Share to Mycobacterium tuberculosis

Share to Protein Conformation

Share to Pyrazinamide

Share to Thermodynamics

Source

Identifiers

PMID: 37837425
DOI: 10.1080/07391102.2023.2268216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Free energy landscape and thermodynamics properties of novel mutations in PncA of pyrazinamide resistance isolates of Mycobacterium tuberculosis.PMID 37837425Read ↗

Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide ResistanceSemantic proximity Read ↗

Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis.Semantic proximity Read ↗

Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistanceSemantic proximity Read ↗

Mechanistic insights into the conformational changes and alterations in residual communications due to the mutations in the pncA Gene of Mycobacterium tuberculosis: A computational perspective for effective therapeutic solutions.Semantic proximity Read ↗

Structural and Dynamic Insights into the W68L, L85P, and T87A Mutations of Mycobacterium tuberculosis Inducing Resistance to Pyrazinamide.Semantic proximity Read ↗

Structural insights of catalytic mechanism in mutant pyrazinamidase of Mycobacterium tuberculosis.Semantic proximity Read ↗

Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran.Semantic proximity Read ↗

Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.Semantic proximity Read ↗

Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis.Semantic proximity Read ↗

A robust computational quest: Discovering potential hits to improve the treatment of pyrazinamide-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Deciphering the mechanism of resistance by novel double mutations in pncA in Mycobacterium tuberculosis using protein structural graphs (PSG) and structural bioinformatic approaches.Semantic proximity Read ↗

S292L mutation in Rv1258c efflux pump drives pyrazinamide efflux and a novel inhibitor designed for co-therapy to improve MDR-TB treatment outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.